Top 5 Physical Rehabilitation Apps for Primary Care Providers

Weekly Dose Podcast: Psoriasis Drug Success, Intranasal Insulin Insights, and New Data on Vaccines and GLP-1 Use

The new position paper faults the absence of a clearly defined, evidence-based ceiling on duration of use for the persistent overuse of systemic corticosteroids for AD management.

September 5th 2025

New FDA Guidance Seeks to Expand Nonopioid Options to Manage Chronic Pain and Curb Misuse

This week’s podcast covers psoriasis trial results, intranasal insulin, COVID-19 booster safety, GLP-1 use in diabetes, and RSV vaccine uptake.

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

Opioids are still prescribed to 1 in 5 US adults with chronic pain because effective alternatives are not available; the FDA guidance supports enhanced research paradigms.

August 28th 2025

Oral Blarcamesine Shows Marked Reduction in Cognitive Decline in Early Alzheimer Disease: Phase 2b/3 Data

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

Merck's 21-Valent Pneumococcal Vaccine Shows Positive Immune Response in At-Risk Children, Adolescents

Once-daily blarcamesine was associated with minimal cognitive decline at 48 weeks, with changes comparable to those observed in prodromal aging.

Duration of Use Guidance Published for Systemic Corticosteroids in Atopic Dermatitis Treatment

Merck's CAPVAXIVE could cover approximately 78% of invasive pneumococcal disease cases in youth with chronic health conditions, vs other approved pneumococcal conjugate vaccines.

Related Content

Weekly Dose Podcast: Psoriasis Drug Success, Intranasal Insulin Insights, and New Data on Vaccines and GLP-1 Use

The new position paper faults the absence of a clearly defined, evidence-based ceiling on duration of use for the persistent overuse of systemic corticosteroids for AD management.

September 5th 2025

New FDA Guidance Seeks to Expand Nonopioid Options to Manage Chronic Pain and Curb Misuse

This week’s podcast covers psoriasis trial results, intranasal insulin, COVID-19 booster safety, GLP-1 use in diabetes, and RSV vaccine uptake.

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

Opioids are still prescribed to 1 in 5 US adults with chronic pain because effective alternatives are not available; the FDA guidance supports enhanced research paradigms.

August 28th 2025

Oral Blarcamesine Shows Marked Reduction in Cognitive Decline in Early Alzheimer Disease: Phase 2b/3 Data

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

Merck's 21-Valent Pneumococcal Vaccine Shows Positive Immune Response in At-Risk Children, Adolescents

Once-daily blarcamesine was associated with minimal cognitive decline at 48 weeks, with changes comparable to those observed in prodromal aging.